RENAL
ECOG E2805
A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma

PROSTATE
CINJ 080805 NJ 2808
A Phase II Study of Docetaxel and Modulation of Autophagy with Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer

ECOG E3805
CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease Prostate Cancer

CINJOG 080803 (NJ 1808)
-Hormone-Dependent PSA Progression after Local Therapy for Prostate Cancer (Stage D0)
Hydroxychloroquine 400mg per day

CINJOG 080811
Phase II trial of Atorvastatin (Lipitor) and Celecoxib in Patients with Hormone-Dependent Prostate-Specific Antigen (Stage D0) Progression After Local Therapy for Prostate Cancer. Must not have had any hormone ablative treatment except for neoadjuvant.

BLADDER
CINJ 080804
A Phase II Multicenter Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naïve Patients with Advanced/Metastatic Bladder Cancer